Storia in 1 fonti

Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs

The first biotech out of incubator and investor Jupiter Bioventures is working on a $75 million Series B to bring its first two drug candidates into clinical testing.

Raccontata da

endpoints.news

Timeline cronologica

lunedì 8 giugno 2026·endpoints.news
Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs
The first biotech out of incubator and investor Jupiter Bioventures is working on a $75 million Series B to bring its first two drug candidates into clinical testing.